You are here

  • Home
  • Archive
  • Volume 17, Issue 2
  • Inhaled anticholinergic medications in older men with chronic obstructive pulmonary disorder are associated with increased odds of acute urinary retention

Article Text

Article menu
Download PDFPDF
Prognosis
Nested case-control study
Inhaled anticholinergic medications in older men with chronic obstructive pulmonary disorder are associated with increased odds of acute urinary retention
  1. Robert Kyskan,
  2. Don D Sin
  1. Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
  1. Correspondence to Don D Sin
    Department of Medicine, University of British Columbia, St Pauls Hospital, 1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; don.sin{at}hli.ubc.ca

https://doi.org/10.1136/ebm.2011.100143

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med 2011;171:914–20.OpenUrlCrossRefPubMedWeb of Science

    Context

    Chronic obstructive pulmonary disease (COPD) affects 1 in 10 individuals more than 40 years of age.1 Many of these patients use inhaled anticholinergic (IAC) medications, often as a first-line therapy.2 Although IACs are generally poorly absorbed from the gastrointestinal and respiratory tracts, approximately 10–15% of the drug make it into the systemic circulation.3 Cholinergic receptors are expressed in prostatic tissue, and their stimulation may cause urinary retention.4 However, the risk of acute urinary retention (AUR) related to IAC use in the older COPD population is not known.

    Methods

    This was a population-based nested case-control study from Ontario, Canada, in which the risk of AUR was compared between …

    View Full Text

    Footnotes

    • Competing interests DDS has received grants from Pfizer and Boehringer Ingelheim, makers of inhaled anticholinergics, as well as from AstraZeneca and GlaxoSmithKline, makers of long-acting β-2 agonists.